Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 2, 2007

Pfizer Obtains Licence from Genencor to Aid in Protein-Based Drug Development

  • Genencor granted Pfizer a nonexclusive license to technology that reportedly enhances the level of expression of secreted polypeptides in microorganisms. According to Genencor, the platform may reduce the cost of developing protein-based drugs.

    "Genencor's ability to improve the efficiency of protein production is widely applicable to many industries," says Michael V. Arbige, Genencor's executive vp for innovation. "As the cost of protein manufacturing has long been a potential barrier to therapeutic development in some cases, Pfizer's use of this technology may create opportunities to develop new and more effective therapies."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »